Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Titel:
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Auteur:
Kantarjian, Hagop M. Shah, Neil P. Cortes, Jorge E. Baccarani, Michele Agarwal, Mohan B. Undurraga, María Soledad Wang, Jianxiang Kassack Ipiña, Juan Julio Kim, Dong-Wook Ogura, Michinori Pavlovsky, Carolina Junghanss, Christian Milone, Jorge H. Nicolini, Franck E. Robak, Tadeusz Van Droogenbroeck, Jan Vellenga, Edo Bradley-Garelik, M. Brigid Zhu, Chao Hochhaus, Andreas